Toll Free: 1-888-928-9744

Keratitis - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Keratitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratitis - Pipeline Review, H2 2016, provides an overview of the Keratitis (Ophthalmology) pipeline landscape.

Keratitis is an inflammation of the cornea. Symptoms include eye redness, eye pain, blurred vision, decreased vision and sensitivity to light. Risk factors include virus infections, injury, climatic condition and reduced immunity. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Keratitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 7 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively for Keratitis.

Keratitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Keratitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Keratitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Keratitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Keratitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Keratitis (Ophthalmology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Keratitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Keratitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Keratitis Overview 7 Therapeutics Development 8 Pipeline Products for Keratitis - Overview 8 Pipeline Products for Keratitis - Comparative Analysis 9 Keratitis - Therapeutics under Development by Companies 10 Keratitis - Therapeutics under Investigation by Universities/Institutes 11 Keratitis - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Keratitis - Products under Development by Companies 15 Keratitis - Products under Investigation by Universities/Institutes 16 Keratitis - Companies Involved in Therapeutics Development 17 Adamis Pharmaceuticals Corporation 17 Dompe Farmaceutici S.p.A. 18 NanoViricides, Inc. 19 ReceptoPharm, Inc. 20 RegeneRx Biopharmaceuticals, Inc. 21 SIFI S.p.A 22 The Medicines Company 23 Keratitis - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 acyclovir sodium - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 B-2088 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 C-31G - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 dipyridamole - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Herpecide - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 IBN-1 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 JDE-004 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 PIM-45 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 polihexanide - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 RGN-259 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 RPI-MN - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Small Molecule for Neurotrophic Keratitis - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Small Molecules to Inhibit ATM for Herpes Keratitis - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Synthetic Peptides for Bacterial Keratitis and Wounds - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 targocil - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 tigecycline - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Keratitis - Dormant Projects 60 Keratitis - Discontinued Products 61 Keratitis - Product Development Milestones 62 Featured News & Press Releases 62 Jun 01, 2016: RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China 62 May 27, 2016: SIFI announces the conclusion of Phase I clinical trial for the development of PHMB an orphan drug for the treatment of Acanthamoeba Keratitis, a rare ocular disease 62 Jan 12, 2016: NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Fransisco on Wednesday 63 Dec 02, 2015: rhNGF, the Dompe Biotech Molecule for the Treatment of Neurotrophic Keratitis, Receives Orphan Drug Designation from the European Medicines Agency 63 Oct 21, 2015: RegeneRx Updates on U.S. Ophthalmic Clinical Trials 64 Sep 30, 2015: RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial 64 Sep 21, 2015: RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy Clinical Trial with RGN-259 65 Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy 65 Sep 25, 2014: EuCornea: Dompe wins the "Best Poster Award" for its preliminary data concerning the use of rhNGF in the treatment of neurotrophic keratitis 66 Jul 23, 2014: Dompe announces the Food and Drug Administration has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 67 Feb 14, 2013: Dompe Announces Enrollment Of First Patient In First International Clinical Trial Of rhNGF For Treatment Of Neurotrophic Keratitis 68 Appendix 69 Methodology 69 Coverage 69 Secondary Research 69 Primary Research 69 Expert Panel Validation 69 Contact Us 69 Disclaimer 70
List of Tables
Number of Products under Development for Keratitis, H2 2016 8 Number of Products under Development for Keratitis - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Keratitis - Pipeline by Adamis Pharmaceuticals Corporation, H2 2016 17 Keratitis - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 18 Keratitis - Pipeline by NanoViricides, Inc., H2 2016 19 Keratitis - Pipeline by ReceptoPharm, Inc., H2 2016 20 Keratitis - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016 21 Keratitis - Pipeline by SIFI S.p.A, H2 2016 22 Keratitis - Pipeline by The Medicines Company, H2 2016 23 Assessment by Monotherapy Products, H2 2016 24 Number of Products by Stage and Target, H2 2016 26 Number of Products by Stage and Mechanism of Action, H2 2016 28 Number of Products by Stage and Route of Administration, H2 2016 30 Number of Products by Stage and Molecule Type, H2 2016 32 Keratitis - Dormant Projects, H2 2016 60 Keratitis - Discontinued Products, H2 2016 61



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify